Health Care · Pharmaceutical Preparations

CRVS Corvus Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 162697186 filings
Russell 2000

CRVS at a glance

Corvus Pharmaceuticals, Inc. (CRVS, SEC CIK 1626971) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Corvus Pharmaceuticals, Inc. (CRVS) shares worth $262.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Arcara Jeffrey on November 13, 2026 of 500 shares at $10.71 per share.
  • In the last 90 days, CRVS insiders reported 4 open-market purchases ($50K) and 0 open-market sales ($0) on Form 4, a net purchase of $50K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
4 buys · 0 sells
Net +$50K
13F holders
24 funds
$262.2M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Clinical-stage biopharma developing targeted immune cell protein inhibitors for immune-mediated diseases, inflammatory diseases, and cancers
  • New emphasis: Soquelitinib advanced to Phase 3 trial for relapsed peripheral T cell lymphoma (PTCL) and initiated Phase 2 trial for moderate-to-severe atopic dermatitis
  • Strategic shift: Expanded focus on immune and inflammatory diseases from oncology, demonstrated by ITK inhibitor’s novel mechanism rebalancing Th1/Th2/Th17/Treg cells
  • Quantitative highlight: Phase 1/1b trial enrolled 75 PTCL patients; Phase 1 atopic dermatitis trial enrolled 72 patients across 4 cohorts with up to 72% EASI score reduction
  • Noteworthy fact: FDA granted Fast Track and Orphan Drug designations for soquelitinib in relapsed PTCL; first clinical evidence of ITK inhibitor therapy efficacy in both cancer and inflammatory disease pathways

Risk Factors

  • Regulatory risk FDA approval delay for soquelitinib with $21.2M R&D spend in 2025, clinical trial costs up $6.0M YoY
  • Macroeconomic risk accumulated deficit $412.3M with net loss $15.3M in 2025, cash runway only through Q2 2028
  • Operational risk manufacturing cost increase $4.8M for soquelitinib in 2025, reflecting supply chain cost pressures
  • Competitive risk dependence on clinical success of soquelitinib vs oncology market innovations, no approved products yet
  • Financial risk reliance on equity funding with $189.4M raised in January 2026 follow-on offering, ATM offering suspended

Management Discussion & Analysis

  • Forward-looking statements included but specifics on management outlook or guidance not given

AI summary of the CRVS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales or collaboration revenue
  • Net loss $20.3M vs $10.2M YoY, operating margin not applicable due to zero revenue
  • Soquelitinib R&D costs $12.5M vs $5.6M, largest program and $6.9M YoY increase
  • Cash used in operations $38.0M, cash resources $202.9M after $189.4M equity offering
  • Funding expected through Q2 2028, additional capital required amid ongoing clinical-development losses

Risk Factors

  • No material changes identified versus the 10-K, with risks largely carried forward
  • Liquidity risk: $202.9 million in cash, equivalents and marketable securities expected to fund operations into Q2 2028
  • Financial performance risk: $52.0 million net loss and $464.3 million accumulated deficit for nine months ended September 30, 2026
  • Regulatory risk: FDA may reject foreign clinical-trial data, potentially requiring additional costly trials
  • Operational risk: Third-party manufacturers remain subject to cGMP failures that could suspend trials or delay approvals
  • Competitive risk: Larger, better-funded oncology companies may develop more effective therapies faster

AI summary of the CRVS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Q3 and nine-month 2026 financial results through September 30, 2026
  • Includes Corvus Pharmaceuticals’ September 30, 2026 financial position

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss $20.3M, or $0.22 per share, versus $10.2M, or $0.12, in Q3 2025
  • R&D expense $17.8M versus $8.5M, reflecting accelerated soquelitinib clinical development
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Corvus Pharmaceuticals’ financial results for the three and six months ended June 30, 2026
  • Financial position as of June 30, 2026 and a business update announced August 6, 2026

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss $18.0M, or $0.19 per share, versus $8.0M loss, reflecting sharply higher development spending
  • Research and development expense $16.0M, up from $7.9M, as enrollment advances across Phase 3 PTCL and Phase 2 atopic dermatitis trials
Filed Jul 22, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Ian T. Clark resigning from Corvus Pharmaceuticals’ board effective July 22, 2026
  • Departure follows over nine years of board service

AI summaries of CRVS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CRVS

Don't miss the next CRVS filing

  • Alerts as it files. A push when CRVS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CRVS, by share count.
  • Ask anything. An AI agent that reads every CRVS filing and answers with sources.

CRVS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Arcara JeffreyBuyNov 13, 2026$10.71
Arcara JeffreyBuyNov 13, 2026$10.37
Arcara JeffreyBuyNov 12, 2026$11.12
Arcara JeffreyBuyNov 11, 2026$11.46
Moore David ScottAJun 11, 2026-
Grais LindaAJun 11, 2026-
Moore David ScottBuyJun 11, 2026$11.53
CLARK IAN TAJun 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$23.4M-$27.5M-$43.0M
Net Income-$27.0M-$62.3M-$15.3M
Balance Sheet
Total Assets$45.6M$68.9M$71.1M
Equity$38.7M$32.6M$61.2M
ROE-69.9%-191.3%-25.0%
Per Share
EPS$-0.56$-1.02$-0.53
Cash Flow
Operating CF-$23.9M-$25.4M-$32.8M
CapEx$34K-$174K

Source: XBRL data in Corvus Pharmaceuticals, Inc. (CRVS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CRVS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CRVS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$262.2M
Q2 202625$401.2M
Q1 202625$348.4M
Q4 202520$141.1M
Q3 202519$86.1M
Q2 202519$43.1M
Q1 202515$23.0M
Q4 202411$21.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CRVS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
SC 13GAug 7, 2026-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
8-KJul 22, 2026Analysis-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 12, 2026Analysis-
4May 20, 2026-
SC 13GMay 15, 2026-
8-KMay 14, 2026Analysis
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
4Apr 27, 2026--
8-KApr 23, 2026Analysis-
8-KMar 13, 2026Analysis-
10-KMar 12, 2026Analysis
8-KMar 12, 2026Analysis-
SC 13GJan 30, 2026-
4Jan 30, 2026-

Related Health Care companies

All Health Care →

CRVS SEC filings: frequently asked questions

Are CRVS insiders buying or selling?

In the last 90 days, Corvus Pharmaceuticals, Inc. (CRVS) officers, directors and 10% owners reported 4 open-market purchases worth $50,475 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CRVS stock?

As of September 30, 2026, the largest Corvus Pharmaceuticals, Inc. (CRVS) holders among the 13F filers tracked by SignalX were BlackRock ($81.8 million), State Street Corp ($38.4 million), Vanguard Capital Management LLC ($38.2 million), T. Rowe Price Group ($35.2 million), Morgan Stanley ($9.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in CRVS's latest 10-K?

In the 10-K filed March 12, 2026, Corvus Pharmaceuticals, Inc. (CRVS) flagged: Regulatory risk FDA approval delay for soquelitinib with $21.2M R&D spend in 2025, clinical trial costs up $6.0M YoY. Macroeconomic risk accumulated deficit $412.3M with net loss $15.3M in 2025, cash runway only through Q2 2028. (AI summary of the Risk Factors section.)

What did CRVS report in its latest 8-K?

Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Q3 and nine-month 2026 financial results through September 30, 2026.

What are the latest CRVS SEC filings?

Corvus Pharmaceuticals, Inc. (CRVS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is CRVS's SEC CIK number?

Corvus Pharmaceuticals, Inc. (CRVS)'s SEC Central Index Key (CIK) is 1626971. EDGAR lists every CRVS filing under that number.

Ask anything about CRVS

The research agent reads CRVS's filings, financials, insider trades and 13F holders, then answers with sources.